Breast tumour tissues of both animals and man contain a receptor system for oestrogen. Oestrogen combines with a high affinity receptor in the cytoplasm of the target cell and the complex is transferred to the nucleus from where the metabolic response of the tissue is directed (De Sombre, 1982; Jordan, 1982) . In the past decade significant advances in the treatment of breast cancer were made after it was discovered that tumours could be classified as oestrogen-receptor (ER)-rich or ERpoor. This classification correlated with the response of the tumour during treatment by hormonal manipulation; ER-poor tumours did not respond whereas from 50-60% of ER-rich tumours did (Henderson & Canellos, 1980; De Sombre, 1982) . Thus the assay of tumour cytosols has become an important tool for the clinician to help in the assessment of treatment protocols. The drugs used for the treatment of breast cancer can be divided into 2 broad categories: One comprises the hormonally-related drugs which includes diethylstilboestrol and the antioestrogen tamoxifen. The other group includes an alkylating agent, cyclophosphamide, the antimetabolites, methotrexate and 5-fluoruracil and the antibiotic adriamycin, which are usually administered in the form of combined intermittent therapy (Henderson & Cannelos, 1980) . It is well established that the oestrogen agonists and antagonists will react with the ER system (Leclercq & Heuson, 1979) . Recently it was demonstrated that 2 non-steroidal antimetabolites used for the treatment of breast cancer would also interact with the ER system of the rat uterus (Di Carlo et al., 1978) . Methotrexate and adriamycin were shown to competitively prevent the binding of oestradiol-17,B to the receptor in vitro. In vivo changes were also produced which suggested that these drugs reacted with the receptor system in a manner similar to oestrogen. These somewhat surprising results have (Cidlowski & Muldoon, 1978; Dix & Jordan, 1980; Horwitz & McGuire, 1980 The assayed concentrations of specifically-bound oestradiol in the incubate were used to construct plots (Scatchard, 1949) (Figure) . When methotrexate was administered to the rats at the same time as oestradiol-17,/ the uterine cytosol receptor content was not changed; the nuclear receptor content appeared to decrease but this change did not achieve significance (P > 0.05). The receptor distribution after oestradiol and adriamycin was similar to the distribution found after oestrogen alone. methotrexate (10-M), therefore it is possible that the inhibition of binding by these drugs of substantially different molecular structure from the steroids is a result of non-specific interaction. A specific interaction was shown by the use of tamoxifen which is well known to possess high affinity for the ER (Dix & Jordan, 1980; Jordan, 1982 Actinomycin D and cycloheximide were without effect upon the in vitro binding of oestradiol-17/3 to the receptor, so it is reasonable to assume that the receptor changes reported in previous papers (Cidlowski & Muldoon, 1978; Dix & Jordan, 1980; Horwitz & McGuire, 1980) reflects the role of protein synthesis in the maintenance of tissue H.A.R. concentrations. Such experiments have led to the conclusion that receptor concentrations are maintained by 2 mechanisms, tle unom synthesis and recycling. Methotrexate, adriamycin and many other drugs used for the treatment of breast cancer will inhibit protein synthesis, so that while the present experiments have failed to demonstrate a direct effect of these drugs upon ER an indirect action via inhibition of receptor protein synthesis cannot be discounted.
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